Zhejiang Kisun Pharmaceutical Co., Ltd., based in Zhejiang and serving the global market, is a modern pharmaceutical enterprise dedicated to the R&D and production of high-quality drug products. The company's production facilities have obtained both Chinese and European GMP certifications, achieving full alignment with international standards through a stringent quality system and standardized management. Kisun has established a deep collaboration with the renowned German pharmaceutical company STADA to jointly produce a variety of high-end drug products, creating synergistic advantages in quality control, technical processes, and market expansion. Building on the quality foundation of dual China-Europe GMP certification and the in-depth partnership with STADA for producing high-quality drug products, Kisun adheres to international standards, drives innovation in R&D, and advances a diverse product pipeline. It is committed to providing safer, more reliable, and trustworthy pharmaceutical solutions for patients worldwide.

Upholding the philosophy of “Quality as the Foundation, Innovation as the Driving Force, and Patients First,” the company continues to increase its investment in R&D and build a robust pipeline of drug candidates with strong market potential and clinical value, covering a wide range of therapeutic areas. Kisun is committed to consistently providing healthcare institutions and patients with safer, more effective and more stable drug product options, striving to become a trustworthy international pharmaceutical partner.

Launched drug products:

Sitafloxacin Tablets

Imatinib Mesylate Tablets

Kisun Pharmaceutical is dedicated to research and development, production, and sales of injections and oral solid dosage forms drug products. We also provide custom processing for clients, along with import and export of pharmaceuticals and technologies, demonstrating very promising development prospects.

To date, we have completed the R&D of more than 10 drug products, including tablets, capsules and injections. In 2022, we plan to scale up 12 drug products, complete validation for 6–8 products, and finalize bioequivalence (BE) studies for 1–2 products.

In 2022, we will also initiate R&D for an additional 6–8 new products. In subsequent years, a similar number of new R&D projects will be added annually, which will significantly enhance our production capacity and better meet market demand.

The company is actively expanding multi-channel operations to accelerate the comprehensive development of our drug products business. In addition to proprietary R&D, we are focusing on CDMO, CRO, and co-development services. We are currently in successful negotiations with several internationally renowned companies regarding these collaborations.

While meeting the R&D and production needs of its own portfolio, the company is also able to provide integrated “pilot-to-commercial” CMC/CMO services covering multiple dosage forms, strengths and batch sizes, offering a one-stop solution that helps partners efficiently advance products from development to commercialization. By building a well-balanced portfolio of generic and innovative drug products and strategically expanding into highly regulated markets such as China, the United States and Europe, as well as developing and emerging markets, Kisun aims to establish a truly global sales footprint and further strengthen its competitiveness in the international pharmaceutical sector, emerging as a strong contender within the industry.